For example, HSP90B1 inhibitor can suppress the proliferation of non-small cell lung cancer (NSCLC) that is refractory to epidermal growth factor receptor (EGFR) inhibitor; downstream STAT3 and ERK1/2 activation was more effectively suppressed by HSP90B1 inhibitor [36,37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.